80424
Di(N-succinimidyl) glutarate
≥97.0% (CHN)
Synonym(s):
DSG
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C13H14N2O8
CAS Number:
Molecular Weight:
326.26
UNSPSC Code:
12161502
NACRES:
NA.25
PubChem Substance ID:
MDL number:
Beilstein/REAXYS Number:
8575145
Quality Level
assay
≥97.0% (CHN)
form
lumps
reaction suitability
reagent type: cross-linking reagent
storage temp.
−20°C
SMILES string
O=C(CCCC(=O)ON1C(=O)CCC1=O)ON2C(=O)CCC2=O
InChI
1S/C13H14N2O8/c16-8-4-5-9(17)14(8)22-12(20)2-1-3-13(21)23-15-10(18)6-7-11(15)19/h1-7H2
InChI key
LNQHREYHFRFJAU-UHFFFAOYSA-N
Packaging
Bottomless glass bottle. Contents are inside inserted fused cone.
Other Notes
Homobifunctional cross-linking reagent; e.g. isolation of insulin receptor.
signalword
Warning
hcodes
Hazard Classifications
Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
target_organs
Respiratory system
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Gloves
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
S M Waugh et al.
Biochemistry, 28(8), 3448-3455 (1989-04-18)
Radiolabeled insulin was affinity cross-linked to purified insulin receptor with six separate bifunctional N-hydroxysuccinimide esters of different lengths. Results were qualitatively identical for each cross-linker in that insulin was predominantly cross-linked through its B chain to the receptor's alpha subunit.
Jing Xu et al.
Cell discovery, 2, 16008-16008 (2016-07-28)
Mixed lineage leukemia protein-1 (MLL1) has a critical role in human MLL1 rearranged leukemia (MLLr) and is a validated therapeutic target. However, its role in regulating global gene expression in MLLr cells, as well as its interplay with MLL1 fusion
Margaret Johnson et al.
Journal of acquired immune deficiency syndromes (1999), 81(4), 463-472 (2019-04-16)
Doravirine is a novel, nonnucleoside reverse transcriptase inhibitor with demonstrated efficacy in treatment-naive adults with HIV-1. In this open-label, active-controlled, noninferiority trial, adults with HIV-1 virologically suppressed for ≥6 months on 2 nucleoside reverse transcriptase inhibitors plus a boosted protease